HRP20000652A2 - Quinolin -4-yl derivatives - Google Patents
Quinolin -4-yl derivatives Download PDFInfo
- Publication number
- HRP20000652A2 HRP20000652A2 HR20000652A HRP20000652A HRP20000652A2 HR P20000652 A2 HRP20000652 A2 HR P20000652A2 HR 20000652 A HR20000652 A HR 20000652A HR P20000652 A HRP20000652 A HR P20000652A HR P20000652 A2 HRP20000652 A2 HR P20000652A2
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- compound
- dihydro
- compounds
- isoquinolin
- Prior art date
Links
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 65
- 150000003839 salts Chemical class 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 230000004770 neurodegeneration Effects 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 7
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- -1 hydroxy, amino Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- ZWZCUJOGAOTAMB-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)quinolin-2-amine Chemical compound C1=CC=CC2=NC(N)=CC(N3CC4=CC=CC=C4CC3)=C21 ZWZCUJOGAOTAMB-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- BXAIQPPVOCFPQA-UHFFFAOYSA-N 1-aminopyrrolidin-3-ol Chemical compound NN1CCC(O)C1 BXAIQPPVOCFPQA-UHFFFAOYSA-N 0.000 claims description 2
- QSITUQDXTNRCQN-UHFFFAOYSA-N 3-[[4-(3,4-dihydro-1h-isoquinolin-2-yl)quinolin-2-yl]amino]propane-1,2-diol Chemical compound C1=CC=CC2=NC(NCC(O)CO)=CC(N3CC4=CC=CC=C4CC3)=C21 QSITUQDXTNRCQN-UHFFFAOYSA-N 0.000 claims description 2
- SPSXCZMMEURJOF-UHFFFAOYSA-N 4-(1,3-dihydroisoindol-2-yl)quinoline Chemical compound C1=CC=C2C(N3CC4=CC=CC=C4C3)=CC=NC2=C1 SPSXCZMMEURJOF-UHFFFAOYSA-N 0.000 claims description 2
- HRDFYQVITWAQGZ-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)quinoline Chemical compound C1=CC=C2C(N3CC4=CC=CC=C4CC3)=CC=NC2=C1 HRDFYQVITWAQGZ-UHFFFAOYSA-N 0.000 claims description 2
- DKDRUNMVVXRCDP-UHFFFAOYSA-N 4-(5-chloro-1,3-dihydroisoindol-2-yl)quinoline Chemical compound C1=CC=C2C(N3CC4=CC=C(C=C4C3)Cl)=CC=NC2=C1 DKDRUNMVVXRCDP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- HVVNJUAVDAZWCB-UHFFFAOYSA-N prolinol Chemical compound OCC1CCCN1 HVVNJUAVDAZWCB-UHFFFAOYSA-N 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- QLWNJDJXRLRDEF-HNNXBMFYSA-N (2s)-1-[[4-(3,4-dihydro-1h-isoquinolin-2-yl)quinolin-2-yl]amino]propan-2-ol Chemical compound C1=CC=CC2=NC(NC[C@@H](O)C)=CC(N3CC4=CC=CC=C4CC3)=C21 QLWNJDJXRLRDEF-HNNXBMFYSA-N 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- 239000000872 buffer Substances 0.000 description 8
- PUNLRQSULOEJRZ-UHFFFAOYSA-N 2-chloro-4-(3,4-dihydro-1h-isoquinolin-2-yl)quinoline Chemical class C1=CC=CC2=NC(Cl)=CC(N3CC4=CC=CC=C4CC3)=C21 PUNLRQSULOEJRZ-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- KNDOFJFSHZCKGT-UHFFFAOYSA-N 4-chloroquinoline Chemical compound C1=CC=C2C(Cl)=CC=NC2=C1 KNDOFJFSHZCKGT-UHFFFAOYSA-N 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- PHGYMGYOULMLHZ-UHFFFAOYSA-N 2-chloro-4-(1,3-dihydroisoindol-2-yl)quinoline Chemical compound C1=CC=CC2=NC(Cl)=CC(N3CC4=CC=CC=C4C3)=C21 PHGYMGYOULMLHZ-UHFFFAOYSA-N 0.000 description 2
- KQKFXROIQIGLRC-UHFFFAOYSA-N 3-[[4-(3,4-dihydro-1h-isoquinolin-2-yl)quinolin-2-yl]amino]propane-1,2-diol;hydrochloride Chemical compound Cl.C1=CC=CC2=NC(NCC(O)CO)=CC(N3CC4=CC=CC=C4CC3)=C21 KQKFXROIQIGLRC-UHFFFAOYSA-N 0.000 description 2
- HXEWMTXDBOQQKO-UHFFFAOYSA-N 4,7-dichloroquinoline Chemical compound ClC1=CC=NC2=CC(Cl)=CC=C21 HXEWMTXDBOQQKO-UHFFFAOYSA-N 0.000 description 2
- YGIPBYFVFWZNNF-UHFFFAOYSA-N 4-(5-chloro-1,3-dihydroisoindol-2-yl)quinoline;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CC4=CC=C(C=C4C3)Cl)=CC=NC2=C1 YGIPBYFVFWZNNF-UHFFFAOYSA-N 0.000 description 2
- BEOVBLPXVFICSP-UHFFFAOYSA-N 4-chloro-6-methoxyquinoline Chemical compound N1=CC=C(Cl)C2=CC(OC)=CC=C21 BEOVBLPXVFICSP-UHFFFAOYSA-N 0.000 description 2
- HDHQZCHIXUUSMK-UHFFFAOYSA-N 4-hydroxy-2-quinolone Chemical compound C1=CC=C2C(O)=CC(=O)NC2=C1 HDHQZCHIXUUSMK-UHFFFAOYSA-N 0.000 description 2
- KDKRSWXFLFTSII-UHFFFAOYSA-N 5-chloro-2,3-dihydro-1h-isoindole Chemical compound ClC1=CC=C2CNCC2=C1 KDKRSWXFLFTSII-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000012320 chlorinating reagent Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XABOFMOULLCGMG-RSAXXLAASA-N (2s)-1-[[4-(3,4-dihydro-1h-isoquinolin-2-yl)quinolin-2-yl]amino]propan-2-ol;hydrochloride Chemical compound Cl.C1=CC=CC2=NC(NC[C@@H](O)C)=CC(N3CC4=CC=CC=C4CC3)=C21 XABOFMOULLCGMG-RSAXXLAASA-N 0.000 description 1
- HXKKHQJGJAFBHI-VKHMYHEASA-N (2s)-1-aminopropan-2-ol Chemical compound C[C@H](O)CN HXKKHQJGJAFBHI-VKHMYHEASA-N 0.000 description 1
- DZNGVRXHTSWTKG-GMUIIQOCSA-N (3r)-1-[4-(3,4-dihydro-1h-isoquinolin-2-yl)quinolin-2-yl]pyrrolidin-3-ol;hydrochloride Chemical compound Cl.C1[C@H](O)CCN1C1=CC(N2CC3=CC=CC=C3CC2)=C(C=CC=C2)C2=N1 DZNGVRXHTSWTKG-GMUIIQOCSA-N 0.000 description 1
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 1
- PMZDQRJGMBOQBF-UHFFFAOYSA-N 1H-quinolin-4-one Natural products C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 1
- GKDNKBYYSALRFK-UHFFFAOYSA-N 2-[[4-(3,4-dihydro-1h-isoquinolin-2-yl)quinolin-2-yl]amino]ethanol;hydrochloride Chemical compound Cl.C1=CC=CC2=NC(NCCO)=CC(N3CC4=CC=CC=C4CC3)=C21 GKDNKBYYSALRFK-UHFFFAOYSA-N 0.000 description 1
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 1
- OUFPYCKWKKEQAG-UHFFFAOYSA-N 4-(1,3-dihydroisoindol-2-yl)quinoline;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CC4=CC=CC=C4C3)=CC=NC2=C1 OUFPYCKWKKEQAG-UHFFFAOYSA-N 0.000 description 1
- PWVDGJFRTYIICF-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)-2-methylquinoline;hydrochloride Chemical compound Cl.C1=CC=CC2=NC(C)=CC(N3CC4=CC=CC=C4CC3)=C21 PWVDGJFRTYIICF-UHFFFAOYSA-N 0.000 description 1
- XAOBKABAOFTVRJ-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)-6-fluoroquinoline;hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2CN1C1=CC=NC2=CC=C(F)C=C21 XAOBKABAOFTVRJ-UHFFFAOYSA-N 0.000 description 1
- HSHLGPJUMBQTJA-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)-7-methoxyquinoline;hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2CN1C1=CC=NC2=CC(OC)=CC=C21 HSHLGPJUMBQTJA-UHFFFAOYSA-N 0.000 description 1
- GGFNQCQFIBGHPD-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)-7-methylquinoline;hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2CN1C1=CC=NC2=CC(C)=CC=C21 GGFNQCQFIBGHPD-UHFFFAOYSA-N 0.000 description 1
- UNGAOJQYQZPXOO-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)-8-fluoroquinoline;hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2CN1C1=C2C=CC=C(F)C2=NC=C1 UNGAOJQYQZPXOO-UHFFFAOYSA-N 0.000 description 1
- RWTKHGDPBDNODO-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)-8-methoxyquinoline;hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2CN1C1=C2C=CC=C(OC)C2=NC=C1 RWTKHGDPBDNODO-UHFFFAOYSA-N 0.000 description 1
- DRBVGUOACDDLPQ-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)quinolin-6-ol;hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2CN1C1=CC=NC2=CC=C(O)C=C21 DRBVGUOACDDLPQ-UHFFFAOYSA-N 0.000 description 1
- GSMGXXUCQXMMCA-UHFFFAOYSA-N 4-(3,4-dihydro-1h-isoquinolin-2-yl)quinoline;hydrochloride Chemical compound Cl.C1=CC=C2C(N3CC4=CC=CC=C4CC3)=CC=NC2=C1 GSMGXXUCQXMMCA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CKTQPWIDUQGUGG-UHFFFAOYSA-N 4-chloro-6-fluoroquinoline Chemical compound N1=CC=C(Cl)C2=CC(F)=CC=C21 CKTQPWIDUQGUGG-UHFFFAOYSA-N 0.000 description 1
- SLBWENCMEQRYEG-UHFFFAOYSA-N 4-chloro-7-methylquinoline Chemical compound ClC1=CC=NC2=CC(C)=CC=C21 SLBWENCMEQRYEG-UHFFFAOYSA-N 0.000 description 1
- NUIMKHDPMIPYFI-UHFFFAOYSA-N 4-chloro-8-fluoroquinoline Chemical compound C1=CN=C2C(F)=CC=CC2=C1Cl NUIMKHDPMIPYFI-UHFFFAOYSA-N 0.000 description 1
- LCYDNBWXXPOMQL-UHFFFAOYSA-N 4-chloro-8-methoxyquinoline Chemical compound C1=CN=C2C(OC)=CC=CC2=C1Cl LCYDNBWXXPOMQL-UHFFFAOYSA-N 0.000 description 1
- WHFKEBBQPCDRND-UHFFFAOYSA-N 4-chloroquinolin-2-amine Chemical compound C1=CC=CC2=NC(N)=CC(Cl)=C21 WHFKEBBQPCDRND-UHFFFAOYSA-N 0.000 description 1
- QXNPFPJBKLAQJG-UHFFFAOYSA-N 4-chloroquinolin-6-ol Chemical compound N1=CC=C(Cl)C2=CC(O)=CC=C21 QXNPFPJBKLAQJG-UHFFFAOYSA-N 0.000 description 1
- 150000005653 4-chloroquinolines Chemical class 0.000 description 1
- SNEHFFDUXILTFJ-UHFFFAOYSA-N 7-chloro-4-(3,4-dihydro-1h-isoquinolin-2-yl)quinoline;hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2CN1C1=CC=NC2=CC(Cl)=CC=C21 SNEHFFDUXILTFJ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- HVVNJUAVDAZWCB-RXMQYKEDSA-N D-prolinol Chemical compound OC[C@H]1CCCN1 HVVNJUAVDAZWCB-RXMQYKEDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- VSGPVHSTVTXREH-UHFFFAOYSA-N quinolin-4-one Chemical compound C1=CC=C[C]2C(=O)C=CN=C21 VSGPVHSTVTXREH-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Description
Predloženi izum odnosi se na spojeve opće formule
[image]
u kojoj
R1 predstavlja vodik, niži alkil, niži alkoksi, hidroksi, amino, nitro, cijano, niži alkil-amino, di-niži alkil-amino ili halogen;
R2 je vodik, niži alkil, amino, pirolidin-3-ol, pirolidin-2-il-metanol ili -NHCH2CHROH;
R3 je vodik ili halogen;
R je vodik, niži alkil ili -CH2OH;
n je 1 ili 2;
i njihove farmaceutski prihvatljive kiselinske adicijske soli.
Spojevi formule I i njihove soli odlikuju se vrijednim terapeutskim svojstvima. Spojevi predloženog izuma su selektivni blokeri podtipa NMDA (N-metil-D-aspartat)-receptora, koji imaju ključnu funkciju u modulaciji djelovanja i plastičnosti neurona, koja im dalje ključnu ulogu u posrednim procesima na kojima se temelji razvoj središnjeg nervnog sistema, kao i učenje i stvaranje pamćenja.
Pod patološkim stanjima akutnih i kroničnih oblika neurodegeneracije, ključni događaj koji uzrokuje smrt neuronske stanice je prekomjerno aktiviranje NMDA receptora. NMDA receptori se sastoje od članova dviju podskupina, naime NR-1 (8 različito povezanih inačica) i NR-2 (A do D) koje potječu od različitih gena. Članovi tih dviju podskupina pokazuju različitu razdiobu u različitim područjima mozga. Heteromerne kombinacije NR-1 članova s različitim NR-2 podskupinama imaju za posljedicu NMDA receptore koji pokazuju različita farmaceutska svojstva. Moguće terapeutske indikacije za specifične blokere podtipa NMDA receptora uključuje akutne oblike neurodegeneracije uzrokovane npr. udarom kapi i traumom mozga, i kronične oblike neurodegeneracija, kao što je Alzheimerova bolest, Parkinsonova bolest, Huntingtonova bolest, ALS (aminotrofna lateralna skleroza) i neurodegeneraciju povezanu s bakterijskim ili virusnim infekcijama, i dodatno, kroničnu i akutnu bol.
Predmet izuma su spojevi formule I i njihove farmaceutski prihvatljive kiselinske adicijske soli, pripravljanje spojeva formule I i njihovih soli, lijekovi koji sadrže spoj formule I ili njegovu farmaceutski prihvatljivu kiselinsku adicijsku sol, proizvodnja takovih lijekova i upotreba spojeva formule I i njihovih farmaceutski prihvatljivih soli za suzbijanje ili prevenciju bolesti, posebno bolesti ili poremećaja gore navedene vrste, i, odnosno, za proizvodnju odgovarajućih lijekova.
Predloženi izum obuhvaća racemične smjese i sve njihove odgovarajuće enantiomere.
Slijedeće definicije općih pojmova, koji se koriste u predloženom opisu, primjenjuju se bez obzira da li se dotični pojam pojavljuje sam ili u kombinaciji.
Kako se ovdje rabi, pojam "niži alkil" označava alkilnu skupinu ravnog ili razgranatog lanca koja ima 1 do 4 ugljikova atoma, na primjer metil, etil, propil, izopropil, butil i slično.
Pojam "halogen" označava klor, jod, fluor i brom.
Pojam "niži alkoksi" označava skupinu u kojoj je alkilni ostatak definiran kao gore.
Pojam "farmaceutski prihvatljiva kiselinska adicijska soli" obuhvaća soli s anorganskim i organskim kiselinama kao što su solna kiselina, dušična kiselina, sumporna kiselina, fosforna kiselina, limunska kiselina, mravlja kiselina, fumarna kiselina, maleinska kiselina, octena kiselina, sukcinska kiselina, vinska kiselina, metansulfonska kiselina, p-toluensulfonska kiselina i slično.
Prednosni spojevi formule I u svrhu predloženog izuma su oni u kojima n je 2, a R1 i R3 predstavljaju vodik. To su slijedeći spojevi:
(RS)-3-[4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin-2-ilamino]-propan-1,2-diol,
(S)-1-[4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin-2-ilamino]-propan-1,2-diol,
4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin-2-ilamin i
4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin.
Daljnji prednosni spojevi predloženog izuma su oni u kojima n je 1, R1 je vodik, a R3 predstavlja vodik ili halogen, na primjer slijedeći spojevi:
4-(5-klor-1,3-dihidro-izoindol-2-il)-kinolin i
4-(1,3-dihidro-izoindol-2-il)-kinolin.
Gore spomenuti spojevi formule I mogu se proizvesti prema izumu
a) reakcijom spoja formule
[image]
s aminom formule
[image]
u spoj formule
[image]
u kojoj R1-R3 i n imaju gore navedena značenja, ili
b) reakcijom spoja formule
[image]
sa spojem formule
HR2 V
u kojoj R1-R3 i n imaju gore navedena značenja, s izuzetkom da R2 nije vodik, niži alkil ili amino, čime se dobije spoj formule I, i
po želji, modifikacijom jednog ili više supstituenata u okviru gore datih definicija, ili
po želji, pretvorbom dobivenog spoja formule I u farmaceutski prihvatljivu sol.
U nastavku su priprave spojeva formule I opisane s više pojedinosti.
U skladu s gore opisanim inačicama postupka i prema dolje opisanoj shemi 1, spojevi formule I mogu se proizvesti poznatim postupcima, na primjer
- reakcijom 2-klor-4-(3,4-dihidro-1H-izokinolin-2-il)-ili 2-klor-4-(1,3-dihidro-izoindol-2-il)-kinolina s primarnim ili sekundarnim aminom, pri 150-160°C, upotrebom čistog amina kao otapala, ili
- reakcijom 4-klor-kinolina s 1,2,3,4-tetrahidro-izokinolinom ili 2,3-dihidro-1H-izoindolom u stehiometrijskom odnosu i pri 140-150°C.
2-klor-4-(3,4-dihidro-1H-izokinolin-2-il)-kinolini i 2-klor-4-(1,3-dihidro-izoindol-2-il)-kinolini su proizvedeni poznatim metodama (Curd, F.H.S.; Raison, C.G.: Rose. F.L.; J. Chem. Soc. 1947, 899) reakcijom 2,4-dihidroksi-kinolina s 1,2,3,4-tetrahidroizokinolinom ili 2,3-dihidro-1H-izoindolom pri 200°C i zatim obradom sa sredstvom za kloriranje kao što je fosforni oksiklorid.
4-klor-kinolini su proizvedeni poznatim metodama reakcijom odgovarajućeg kinolin-4-ona sa sredstvom za kloriranje kao što je fosforni oksiklorid (shema 1)
[image]
Farmaceutski prihvatljive soli mogu se proizvesti u skladu s metodama koje su kao takove poznate i bliske svakom stručnjaku. Kiselinske adicijske soli spojeva formule I posebno su prikladne za farmaceutsku upotrebu.
U shemi 1 opisani su postupci za pripravljanje spojeva formule I koji polaze od poznatih spojeva, komercijalnih proizvoda ili od spojeva koji se mogu proizvesti na uobičajeni način.
Pripravljanje spojeva formule I opisano je s više pojedinosti u radnim primjerima 1-18.
Kako je ranije spomenuto, spojevi formule I i njihove farmaceutski upotrebljive kiselinske adicijske soli imaju vrijedna farmakodinamička svojstva. Oni su selektivni blokeri podtipa NMDA receptora, koji ima ključnu funkciju u modulaciji djelovanja i plastičnosti neurona, koja im daje ključnu ulogu u posrednim procesima na kojima se temelji razvoj CNS-a kao i učenje i stvaranje pamćenja.
Spojevi su istraženi u skladu s ispitivanjima koja su opisana u nastavku.
Metoda ispitivanja
Vezanje 3H-Ro-6981 (Ro 25-6981 je [R-(R*, S*)]-a-(4-hidroksifenil)-b-metil-4-(fenil-metil)-1-piperidin propanol)
Upotrijebljeni su mužjaci Füllinsdorf albino štakora težine između 150 i 200 grama. Membrane su pripravljane homogenizacijom čitavog mozga umanjenog za cerebelum i medulu oblongatu s Polytronom (10.000 okr./min, 30 sekundi) u 25 volumena hladnog pufera Tris-HCl 50 mM, EDTA 10 mM, pH 7,1. Homogenat je centrifugiran 10 minuta pri 4°C i pri 48.000 g. Talog je ponovno suspendiran pomoću Polytrona u istom volumenu pufera i homogenat je inkubiran 10 minuta pri 37°C. Nakon centrifugiranja, talog je homogeniziran u istom puferu i smrznut pri -80°C najmanje 16 sati, ali ne dulje od 10 dana. Za ispitivanje vezanja, homogenat od odmrznut pri 37°C, centrifugiran i talog je ispran tri puta kao gore u hladnom puferu Tris-HCl 5 mM, pH 7,4. Krajnji talog je ponovno suspendiran u istom puferu i upotrijebljen pri krajnjoj koncentraciji od 200 mg proteina/ml.
Pokusi vezanja 3H-Ro 25-6981 provedeni su upotrebom pufera Tris-HCl 50 mM, pH 7,4. Za pokuse premještanja upotrijebljen je 5 nM 3H-Ro 25-6981, a nespecifično vezanje izmjereno je upotrebom 10 mM tetrahidrokinolina i to uobičajeno iznosi 10% od ukupnog. Vrijeme inkubacije bilo je 2 sata pri 4°C i pokus je zaustavljen filtracijom kroz Whatmann GF/B filtere od staklenih vlakana (Unifilter-96, Packard, Zurich, Švicarska). Filteri su isprani 5 puta s hladnim puferom. Radioaktivnost na filteru izračunata je na Packard Top-count scintilacijskom brojaču za mikrotitarske pločice nakon dodatka 40 ml mikroscinta 40 (Canberra Packard S.A., Zurich, Švicarska).
Učinci spojeva izmjereni su upotrebom najmanje 8 koncentracija i s najmanje jednim ponavljanjem. Skupljene normalizirane vrijednosti su analizirane upotrebom računalnog programa za ne-linearnu regresiju koji daje IC50 s njenom relativnom gornjom i donjom granicom pouzdanosti od 90%.
Vrijednost IC50 (µM) prednosnih spojeva formule I, ispitanih u skladu s gore opisanim metodama, je <0,1 µM.
Primjeri nekih vrijednosti IC50 dati su u dolnjoj tablici.
[image]
Spojevi formule I i njihove soli, kako su ovdje opisani, mogu se ugraditi u standardne farmaceutske oblike doziranja, na primjer za oralnu ili parenteralnu aplikaciju s uobičajenim farmaceutskim pomoćnim materijalima, na primjer organskim ili anorganskim inertnim nosećim materijalima, kao što je voda, želatina, laktoza, škrob, magnezijev stearat, talk, biljna ulja, gume, polialkilen-glikoli i slično. Farmaceutski pripravci mogu se upotrijebiti u krutom obliku, na primjer kao tablete, čepići, kapsule, ili u tekućem obliku, na primjer kao otopine, suspenzije ili emulzije. Mogu se dodati i farmaceutski pomoćni materijali koji uključuju konzervanse, stabilizatore, sredstva za kvašenje ili emulgiranje, soli za podešavanje osmotskog tlaka ili soli koje djeluju kao puferi. Farmaceutski pripravci mogu također sadržavati i druge terapeutski aktivne tvari.
Doziranje se može mijenjati u širokim granicama i podešava se, naravno, prema pojedinačnim zahtjevima u svakom posebnom slučaju. U slučaju oralnog davanja, doza se kreće u području od pribl. 0,1 mg po dozi do pribl. 1000 mg dnevno spoja opće formule I, iako se gornju granicu može prekoračiti ako se to pokaže indikativnim.
Slijedeći primjeri ilustriraju predloženi izum s više pojedinosti. Međutim, oni nisu predviđeni za ograničenje njegove svrhe ni na koji način. Sve temperature su navedene u stupnjevima Celsiusa.
Primjer 1
(RS)-3-[4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin-2-ilamino]-propan-1,2-diol hidroklorid
2-klor-4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin (0,44 g, 1,5 mmola) i (RS)-3-amino-1,2-propandiol (0,82 g, 9,0 mmolova) miješaju se i griju 5 sati pri 150-160°C. Reakcijsku smjesu se ohladi na sobnu temperaturu i doda se vodu (15 ml). Dobivenu krutu tvar se odfiltrira, osuši i kromatografira preko silika gela (CH2Cl2-MeOH, 19:1 i zatim 9:1), čime se dobije bijelu pjenu koju se otopi u MeOH. Doda se HCl-Et2O, čime se dobije (RS)-3-[4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin-2-ilamino]-propan-1,2-diol hidroklorid (0,4 g, 69%) kao bijela pjena, MS: m/e = 349 (M+).
Po općoj metodi iz primjera 1 proizvedeni su spojevi iz primjera 2 do primjera 5.
Primjer 2
2-[4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin-2-ilamino]-etanol hidroklorid
Naslovni spoj, MS: m/e = 320,3 (M+H+), proizveden je iz 2-klor-4-(3,4-dihidro-1H-izokinolin-2-il)-kinolina i etanolamina.
Primjer 3
(S)-1-[4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin-2-ilamino]-propan-2-ol hidroklorid
Naslovni spoj, MS: m/e = 334,3 (M+H+), proizveden je iz 2-klor-4-(3,4-dihidro-1H-izokinolin-2-il)-kinolina i S(+)-1-amino-2-propanola.
Primjer 4
(R)-1-[4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin-2-il]-pirolidin-3-ol hidroklorid
Naslovni spoj, talište 270-274°C, [α]20D = -34° (c = 0,54, metanol) i MS: m/e = 346,3 (M+H+), proizveden je iz 2-klor-4-(3,4-dihidro-1H-izokinolin-2-il)-kinolina i (R)-3-hidroksipirolidina.
Primjer 5
(R)-{144-(3,4-dihidro-1H-izokinolin-2-il)-kinolin-2-il]-pirolidin-2-il}-metanol
Naslovni spoj, talište 74-80°C, [α]20D = +63,2° (c = 0,53, metanol) i MS: m/e = 360,3 (M+H+), proizveden je iz 2-klor-4-(3,4-dihidro-1H-izokinolin-2-il)-kinolina i D-prolinola.
Primjer 6
4-(5-klor-1,3-dihidro-izoindol-2-il)-kinolin hidroklorid
Mješavinu 4-klorkinolina (0,245 g, 1,5 mmola) i 5-klor-2,3-dihdiro-1H-izoindola (0,23 g, 1,5 mmola) grije se 4 sata pri 140-150°C pod argonom i zatim se ohladi na sobnu temperaturu. Sirov proizvod se prekristalizira iz metanola, čime se dobije 4-(5-klor-1,3-dihidro-izoindol-2-il)-kinolin hidroklorid (0,115 g, 24%) kao bijela kruta tvar, talište 270-275°C i MS: m/e = 280 (M+).
5-klor-2,3-dihidro-1H-izoindol je poznati spoj i proizveden je po metodi opisanoj u slijedećoj publikaciji: EP 343560.
Po općoj metodi iz primjera 6 proizvedeni su spojevi iz primjera 7 do primjera 18.
Primjer 7
4-(1,3-dihidro-izoindol-2-il)-kinolin hidroklorid
Naslovni spoj, talište 264-267°C i MS: m/e = 247,3 (M+H+), proizveden je iz 4-klorkinolina i 2,3-dihidro-1H-izoindola.
Primjer 8
4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin-2-ilamin
Naslovni spoj, MS: m/e = 276,3 (M+H+), proizveden je iz 4-klor-kinolin-2-ilamina i 1,2,3,4-tetrahidro-izokinolina.
Primjer 9
4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin hidroklorid
Naslovni spoj, talište 200°C i MS: m/e = 260 (M+), proizveden je iz 4-klor-kinolina i 1,2,3,4-tetrahidro-izokinolina.
Primjer 10
Naslovni spoj, talište 218-219°C i MS: m/e = 291,2 (M+H+), proizveden je iz 4-klor-6-metoksi-kinolina i 1,2,3,4-tetrahidro-izokinolina.
Primjer 11
4-(3,4-dihidro-1H-izokinolin-2-il)-7-metoksi-kinolin hidroklorid
Naslovni spoj, MS: m/e == 291,2 (M+H+), proizveden je iz 4-klor-6-metoksi-kinolina i 1,2,3,4-tetrahidro-izokinolina.
Primjer 12
4-(3,4-dihidro-1H-izokinolin-2-il)-8-metoksi-kinolin hidroklorid
Naslovni spoj, talište 240°C, MS: m/e = 291,2 (M+H+), proizveden je iz 4-klor-8-metoksi-kinolina i 1,2,3,4-tetrahidro-izokinolina.
Primjer 13
4-(3,4-dihidro-1H-izokinolin-2-il)-7-metil-kinolin hidroklorid
Naslovni spoj, talište 251-252°C, MS: m/e = 275,3 (M+H+), proizveden je iz 4-klor-7-metil-kinolina i 1,2,3,4-tetrahidro-izokinolina.
Primjer 14
4-(3,4-dihidro-1H-izokinolin-2-il)-2-metil-kinolin hidroklorid
Naslovni spoj, talište 210-211°C, MS: m/e = 275,3 (M+H+), proizveden je iz 4-klorkinolina i 1,2,3,4-tetrahidroizokinolina.
Primjer 15
7-klor-4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin hidroklorid
Naslovni spoj, MS: m/e = 295,3 (M+H+), proizveden je iz 4,7-diklorkinolina i 1,2,3,4-tetrahidroizokinolina.
Primjer 16
4-(3,4-dihidro-1H-izokinolin-2-il)-8-fluor-kinolin hidroklorid
Naslovni spoj, MS: m/e = 279,2 (M+H+), proizveden je iz 4-klor-8-fluor-kinolina i 1,2,3,4-tetrahidro-izokinolina.
Primjer 17
4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin-6-ol hidroklorid
Naslovni spoj, MS: m/e = 277,2 (M+H+), proizveden je iz 4-klor-kinolin-6-ola i 1,2,3,4-tetrahidroizokinolina.
Primjer 18
4-(3,4-dihidro-1H-izokinolin-2-il)-6-fluor-kinolin hidroklorid
Naslovni spoj, MS: m/e = 279,2 (M+H+), proizveden je iz 4-klor-6-fluor-kinolina i 1,2,3,4-tetrahidro-izokinolina.
Primjer A
Formulacija tableta (mokro granuliranje)
[image]
Proizvodni postupak
1. Miješanje sastojaka 1, 2, 3 i 4 i granuliranje s pročišćenom vodom.
2. Sušenje granulata pri 50°C.
3. Propuštanje granulata kroz prikladni mlin.
4. Dodavanje sastojka 5 i miješanje 5 minuta; prešanje na prikladnoj preši.
Primjer B
Formulacija za kapsule
[image]
Proizvodni postupak
1. Miješanje sastojaka 1, 2 i 3 u prikladnoj miješalici 30 minuta.
2. Dodavanje sastojaka 4 i 5 i miješanje 3 minuta.
3. Punjenje prikladnih kapsula.
4. Dodavanje sastojka 5 i miješanje 5 minuta; prešanje na prikladnoj preši.
Claims (12)
1. Spojevi formule
[image]
naznačeni time, da
R1 predstavlja vodik, niži alkil, niži alkoksi, hidroksi, amino, nitro, cijano, niži alkil-amino, di-niži alkil-amino ili halogen;
R2 je vodik, niži alkil, amino, pirolidin-3-ol, pirolidin-2-il-metanol ili -NHCH2CHROH;
R3 je vodik ili halogen;
R je vodik, niži alkil ili -CH2OH;
n je 1 ili 2;
i njihove farmaceutski prihvatljive kiselinske adicijske soli.
2. Spojevi formule I prema zahtjevu 1, naznačeni time, da n je 2, a R1 i R3 predstavljaju vodik.
3. Spojevi formule I prema zahtjevu 2, naznačeni time, da su to
(RS)-3-[4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin-2-ilamino]-propan-1,2-diol,
(S)-1-[4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin-2-ilamino]-propan-2-ol,
4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin-2-ilamin i
4-(3,4-dihidro-1H-izokinolin-2-il)-kinolin.
4. Spojevi formule I prema zahtjevu 1, naznačeni time, da n je 1, R1 je vodik, a R3 predstavlja vodik ili halogen.
5. Spojevi formule I prema zahtjevu 4, naznačeni time, da su to
4-(5-klor-1,3-dihidro-izoindol-2-il)-kinolin i
4-(1,3-dihidro-izoindol-2-il)-kinolin.
6. Lijek, naznačen time, da sadrži jedan ili više spojeva formule I prema bilo kojem zahtjevu od 1 do 5, ili njegovu farmaceutski prihvatljivu sol, i inertan nosač, za liječenje bolesti.
7. Lijek prema zahtjevu 6, naznačen time, da se upotrebljava za liječenje bolesti koje se temelje na terapeutskim indikacijama za specifične blokere podtipa NMDA receptora, a koje uključuju akutne oblike neurodegeneracije uzrokovane, npr. udarom kapi i traumom mozga, i kronične oblike neurodegeneracije, kao što je Alzheimerova bolest, Parkinsonova bolest, Huntingtonova bolest, ALS (amiotrofna lateralna skleroza) i neurodegeneracija povezana s bakterijskim ili virusnim infekcijama, i kronična ili akutna bol.
8. Postupak za proizvodnju spoja formule I prema zahtjevu 1, naznačen time, da uključuje
a) reakciju spoja formule
[image]
s aminom formule
[image]
u spoj formule
[image]
u kojoj R1 do R3 i n imaju značenja navedena u zahtjevu 1, ili
b) reakciju spoja formule
[image]
sa spojem formule
HR2 V
u kojoj R1 do R3 i n imaju značenja navedena u zahtjevu 1, s izuzetkom da R2 nije vodik, niži alkil ili amino, čime se dobije spoj formule I, i
po želji, modifikaciju jednog ili više supstituenata u okviru gore datih definicija, ili
po želji, pretvorbu dobivenog spoja formule I u farmaceutski prihvatljivu sol.
9. Spoj formule I prema bilo kojem zahtjevu od 1 do 5, naznačen time, da je proizveden postupkom prema zahtjevu 8 ili ekvivalentnom metodom.
10. Upotreba spoja spoj formule I prema bilo kojem zahtjevu od 1 do 5, naznačena time, da se on koristi za liječenje bolesti.
11. Upotreba spoja spoj formule I prema zahtjevu 10, naznačena time, da se on koristi za liječenje bolesti koje se temelje na terapeutskim indikacijama za specifične blokere podtipa NMDA receptora, a koje uključuju akutne oblike neurodegeneracije uzrokovane, npr. udarom kapi i traumom mozga, i kronične oblike neurodegeneracije, kao što je Alzheimerova bolest, Parkinsonova bolest, Huntingtonova bolest, ALS (amiotrofna lateralna skleroza) i neurodegeneracija povezana s bakterijskim ili virusnim infekcijama, te akutni ili kronični bol, ili za proizvodnju lijeka koji sadrži takav spoj.
12. Izum, naznačen time, da je u skladu s gornjim opisom.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99120131 | 1999-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20000652A2 true HRP20000652A2 (en) | 2001-12-31 |
Family
ID=8239160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20000652A HRP20000652A2 (en) | 1999-10-08 | 2000-10-03 | Quinolin -4-yl derivatives |
Country Status (26)
Country | Link |
---|---|
US (1) | US6339093B1 (hr) |
EP (1) | EP1090917B1 (hr) |
JP (1) | JP3385318B2 (hr) |
KR (1) | KR100398562B1 (hr) |
CN (1) | CN1162424C (hr) |
AR (1) | AR032601A1 (hr) |
AT (1) | ATE313538T1 (hr) |
AU (1) | AU777881B2 (hr) |
BR (1) | BR0004709A (hr) |
CA (1) | CA2322309C (hr) |
DE (1) | DE60024947T2 (hr) |
DK (1) | DK1090917T3 (hr) |
EG (1) | EG23872A (hr) |
ES (1) | ES2254095T3 (hr) |
HR (1) | HRP20000652A2 (hr) |
HU (1) | HUP0003938A2 (hr) |
ID (1) | ID27526A (hr) |
IL (1) | IL138916A0 (hr) |
MA (1) | MA26753A1 (hr) |
MX (1) | MXPA00009771A (hr) |
NO (1) | NO20005031L (hr) |
NZ (1) | NZ507303A (hr) |
PE (1) | PE20010660A1 (hr) |
PL (1) | PL343057A1 (hr) |
TR (1) | TR200002893A3 (hr) |
ZA (1) | ZA200005447B (hr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
US7375136B2 (en) * | 2001-03-08 | 2008-05-20 | Emory University | pH-dependent NMDA receptor antagonists |
US6831087B2 (en) * | 2001-11-09 | 2004-12-14 | Hoffmann-La Roche Inc. | Pyridine substituted isoquinoline derivatives |
US7005432B2 (en) * | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
PT2167469E (pt) * | 2007-06-18 | 2012-11-20 | Richter Gedeon Nyrt | Derivados de sulfonil-quinoleína |
US8420680B2 (en) * | 2007-06-29 | 2013-04-16 | Emory University | NMDA receptor antagonists for neuroprotection |
CA2700841A1 (en) * | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
JP6969800B2 (ja) * | 2016-05-04 | 2021-11-24 | ジェノシアンス ファルマ | 増殖性疾患の治療に使用される置換2,4−ジアミノ−キノリン誘導体 |
EP3558318B1 (en) | 2016-12-22 | 2023-12-20 | Novartis AG | Nmda receptor modulators and uses thereof |
IL280474B2 (en) | 2018-08-03 | 2023-09-01 | Cadent Therapeutics Inc | Heteroaromatic nmda receptor modulators and their uses |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8409745D0 (en) * | 1984-04-14 | 1984-05-23 | Beecham Group Plc | Active compounds |
US4560692A (en) * | 1984-07-18 | 1985-12-24 | Hoffmann-La Roche Inc. | 4-Piperidino-2-phenylquinolines |
GB8716972D0 (en) * | 1987-07-17 | 1987-08-26 | Pfizer Ltd | Treatment of cardiac arrhythmias |
JPH0262875A (ja) | 1988-05-23 | 1990-03-02 | Wakunaga Pharmaceut Co Ltd | 新規イソインドリン誘導体 |
US4992448A (en) * | 1989-10-24 | 1991-02-12 | Hoechst-Roussel Pharmaceuticals Inc. | Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders |
US5304554A (en) * | 1990-04-27 | 1994-04-19 | Emory University | 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation |
GB9203798D0 (en) * | 1992-02-21 | 1992-04-08 | Fujisawa Pharmaceutical Co | Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
GB9305644D0 (en) * | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
US5567718A (en) * | 1994-08-11 | 1996-10-22 | Hoechst Marion Roussel Inc. | 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors |
ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
-
2000
- 2000-09-26 US US09/669,648 patent/US6339093B1/en not_active Expired - Fee Related
- 2000-09-29 CN CNB001290843A patent/CN1162424C/zh not_active Expired - Fee Related
- 2000-10-02 DK DK00121561T patent/DK1090917T3/da active
- 2000-10-02 EP EP00121561A patent/EP1090917B1/en not_active Expired - Lifetime
- 2000-10-02 ES ES00121561T patent/ES2254095T3/es not_active Expired - Lifetime
- 2000-10-02 DE DE60024947T patent/DE60024947T2/de not_active Expired - Lifetime
- 2000-10-02 AT AT00121561T patent/ATE313538T1/de not_active IP Right Cessation
- 2000-10-03 PE PE2000001045A patent/PE20010660A1/es not_active Application Discontinuation
- 2000-10-03 NZ NZ507303A patent/NZ507303A/xx unknown
- 2000-10-03 HR HR20000652A patent/HRP20000652A2/hr not_active Application Discontinuation
- 2000-10-04 CA CA002322309A patent/CA2322309C/en not_active Expired - Fee Related
- 2000-10-04 ID IDP20000858D patent/ID27526A/id unknown
- 2000-10-04 TR TR2000/02893A patent/TR200002893A3/tr unknown
- 2000-10-04 JP JP2000304354A patent/JP3385318B2/ja not_active Expired - Fee Related
- 2000-10-04 MA MA26080A patent/MA26753A1/fr unknown
- 2000-10-04 EG EG20001265A patent/EG23872A/xx active
- 2000-10-05 AR ARP000105238A patent/AR032601A1/es not_active Application Discontinuation
- 2000-10-05 IL IL13891600A patent/IL138916A0/xx unknown
- 2000-10-05 MX MXPA00009771A patent/MXPA00009771A/es active IP Right Grant
- 2000-10-05 ZA ZA200005447A patent/ZA200005447B/xx unknown
- 2000-10-06 BR BR0004709-0A patent/BR0004709A/pt not_active Application Discontinuation
- 2000-10-06 AU AU64100/00A patent/AU777881B2/en not_active Ceased
- 2000-10-06 HU HU0003938A patent/HUP0003938A2/hu unknown
- 2000-10-06 NO NO20005031A patent/NO20005031L/no not_active Application Discontinuation
- 2000-10-07 KR KR10-2000-0059049A patent/KR100398562B1/ko not_active IP Right Cessation
- 2000-10-09 PL PL00343057A patent/PL343057A1/xx not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60225274T2 (de) | Chinolinderivate als liganden für den neuropeptid-y-rezeptor | |
DE60218037T2 (de) | Neue indolderivate mit affinität zum 5-ht6-rezeptor | |
CA2704000C (en) | Combination of anti-angiogenic substance and anti-tumor platinum complex | |
DE60114227T2 (de) | 2,4-substituierte pyridinderivate | |
HRP20000652A2 (en) | Quinolin -4-yl derivatives | |
AU2001239331A1 (en) | Derivatives of quinoline as alpha-2 antagonists | |
DE69824025T2 (de) | 6,7-asymmetrisch disubstituierte chinoxalincarbonsäurederivate, additionssalze davon und verfahren zur herstellung von beiden | |
KR20100020465A (ko) | 야누스 키나제의 티로신 키나제 활성의 억제제로서의 퀴녹살린 유도체 | |
US5776935A (en) | Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission | |
WO2012044090A2 (ko) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 | |
DE60129154T2 (de) | Neuartige verbindungen | |
DE60100621T2 (de) | 4-heteroaryl-1,4-diazabicyclo 3.2.2.]nonane, ihre herstellung und ihre therapeutische anwendung | |
DE69829317T2 (de) | Tetrahydrobenzindol-derivate | |
TW530055B (en) | Atropisomers 3-heteroaryl-4(3H)-quinazolinones | |
CN108349947A (zh) | 四氢吲唑及其医药用途 | |
TW202342037A (zh) | 治療腦腫瘤和神經母細胞瘤之方法 | |
CN104903300A (zh) | Comt抑制剂 | |
WO2010038803A1 (ja) | 2-インドールアクリルアミド類縁体 | |
TW200800913A (en) | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | |
HRP20000639A2 (en) | Quinolin-4yl derivatives i | |
AU2014229401B2 (en) | Pyrazolylbenzo[d]imidazole derivatives | |
HUE028972T2 (en) | 7- (Heteroarylamino) -6,7,8,9-tetrahydropyrido [1,2-a] indole acetic acid derivatives and their use as prostaglandin D2 receptor modulators | |
US6593324B2 (en) | Dervatives of quinoline as alpha-2 antagonists | |
CN104592233A (zh) | 用于治疗神经变性和神经精神紊乱的桥头胺环稠合吲哚和二氢吲哚 | |
JPH04128288A (ja) | キノロンカルボン酸誘導体及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
OBST | Application withdrawn |